Trials / Unknown
UnknownNCT02961270
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icotinib | Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-12-01
- Completion
- 2018-08-01
- First posted
- 2016-11-10
- Last updated
- 2016-11-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02961270. Inclusion in this directory is not an endorsement.